Sarep­ta to col­lab­o­rate with Genethon on DMD gene ther­a­py; Chi­nese in­vestors pull back on Pluris­tem in­vest­ment

→ Cam­bridge, MA-based Sarep­ta $SRPT is dou­bling down on new work fo­cused on de­vel­op­ing a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy. The biotech inked a deal to col­lab­o­rate with the non­prof­it Genethon, which has been work­ing on an­i­mal mod­els of the dis­ease. “Our agree­ment with Genethon strength­ens our on­go­ing com­mit­ment to pa­tients and is aligned with our strat­e­gy of build­ing the in­dus­try’s most com­pre­hen­sive fran­chise in DMD,” stat­ed Ed­ward Kaye, Sarep­ta’s chief ex­ec­u­tive of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER